Evident has officially completed the acquisition of CrestOptics S.p.A., enhancing capabilities in advanced optical imaging systems for life sciences.

NB Bancorp, Inc. announces its impressive financial results for the second quarter of 2026, showcasing growth in income and assets. A cash dividend is also declared.

Bracco supports the ASNC statement that cardiac PET with myocardial blood flow quantification should be the standard for coronary artery disease evaluations, enhancing diagnostic accuracy.

Q32 Bio announces participation in the 25th Annual Needham Virtual Healthcare Conference, showcasing their innovative therapies for alopecia areata and autoimmune diseases.

Stealth BioTherapeutics has received a significant grant from the MRC Business Engagement Fund for pioneering research into mitochondrial disease treatments via SBT-589.

NB Bancorp, Inc. reports robust financial results for Q3 2025, with net income of $15.4 million and a quarterly cash dividend declaration.

NB Bancorp and Provident Bancorp have received all the necessary regulatory approvals for their merger, targeted for completion in November 2025.

MLAB Biosciences has appointed Dr. Edward M. Kaye as Chair of its Scientific Advisory Board, aiming to enhance their neuromuscular therapy developments.

NB Bancorp and Provident Bancorp have finalized a merger agreement aimed at strategic growth in Massachusetts and New Hampshire, enhancing their service offering.